AbbVie
7 articles
Industry NewsAbbVie / Bristol Myers SquibbBioSpace
Two Neuro Mega-Deals, Two Approvals, Still No Clear Winner
- AbbVie paid $8.7 billion for Cerevel and Bristol Myers Squibb $14 billion for Karuna in late 2023. Each now has an approved drug: Cobenfy since 2024 and AbbVie's Parkinson's drug Juvmo since September.
- Emraclidine failed two Phase 2 schizophrenia studies, while Cobenfy sales have repeatedly missed expectations; its Alzheimer's psychosis readouts have slipped to early 2027.
- Analysts see it as too early to call, with Juvmo's peak sales unlikely to fully justify the Cerevel price.
The two deals were bets on different risks: BMS bought a de-risked first-in-class launch and is now paying for slow uptake and tolerability, while AbbVie bought earlier-stage assets and absorbed a clinical failure. Cobenfy's Alzheimer's psychosis data in 2027 is the swing factor, since it could expand the label well beyond a crowded schizophrenia market.
Industry NewsAbbVie / Nxera PharmaEndpoints News
AbbVie Licenses Nxera's Gut-Targeted EP4 Agonist for IBD in a Deal Worth Up to $1.47B
- AbbVie is licensing Nxera Pharma's EP4 receptor agonist program, aimed at inflammatory bowel disease, with $100 million upfront.
- Development and commercial milestones could add up to $1.37 billion.
- Nxera, through its UK subsidiary, hands over global rights to the gut-targeting program.
AbbVie already owns two big IBD franchises built on IL-23 and JAK inhibition, so a gut-restricted EP4 agonist reads as a mechanism hedge aimed at mucosal healing rather than another immunosuppressant. Upfront is under a tenth of the headline, a typical back-loaded structure. The open question is whether gut restriction holds in patients; EP4 agonists have a history of systemic exposure problems, so early PK and mucosal-biopsy data are what to watch.
Industry NewsAbbVie / Brise PharmaceuticalsEndpoints News
AbbVie and Brise reveal migraine pact for two preclinical programs worth up to $757 million
- AbbVie and Brise Pharmaceuticals have disclosed an agreement covering two preclinical migraine programs.
- Potential aggregate deal value is up to US$757 million, plus royalties on future sales.
- Brise leads discovery work, while AbbVie handles global development and commercialization.
- Brise reports having already hit several near-term milestones; the milestones achieved, the payments and any upfront amount were not disclosed.
Up to $757M sounds large, but for two preclinical programs it is mostly milestone paper, and the undisclosed upfront is the number that tells you AbbVie's conviction. Why disclose a 2024 deal only now? Migraine is crowded with CGRP agents, so the novelty of Brise's mechanism is what to watch, plus any IND timing.
Industry NewsAbbVieBioSpace
AbbVie Beats Again on Skyrizi, Rinvoq and Neuroscience and Signals Bolt-Ons, Not Another Allergan
- Third-quarter sales and earnings beat consensus and full-year EPS guidance was raised; Skyrizi and Rinvoq more than offset the Humira decline, and Skyrizi's full-year projection was lifted for the third time this year.
- Neuroscience was the quarter's standout, growing close to 20%, led by Vraylar, Vyalev, Qulipta and Ubrelvy. Aesthetics was soft.
- The CEO prefers bolt-on acquisitions to a transformational deal, saying the portfolio is already broad; net debt is around $60 billion.
The Humira cliff is now a solved problem, which frees AbbVie to be selective. Bolt-ons in neuroscience and immunology fit that. The weak aesthetics line is the one to watch: it is the highest-margin consumer-facing franchise, and its softness is the main reason a diversifying deal could come back onto the table.
Industry NewsAbbVieBioSpace
AbbVie's lutikizumab meets Phase 3 endpoints in hidradenitis suppurativa, but analysts expected more
- AbbVie reported late-stage results for lutikizumab, its skin disease candidate, with the trial meeting multiple endpoints and reducing abscess burden.
- Some analysts called the data disappointing, raising questions about the drug's commercial prospects.
- The company is eyeing regulatory filings in 2027.
A 2027 filing target despite a lukewarm readout suggests AbbVie sees lutikizumab as a pipeline-refill play, not a breakout. Hidradenitis suppurativa is crowded with established IL-17 options, so hitting endpoints without clearly beating them leaves differentiation thin. With Humira erosion ongoing, AbbVie likely values a dermatology follow-on even at modest peak sales.
Industry NewsGenmab / AbbVieFierce Biotech
Genmab's Rina-S posts durable phase 2 responses in platinum-resistant ovarian cancer
- Genmab reported phase 2 RAINFOL-01 data for the ADC rinatabart sesutecan (Rina-S): a 45.9% confirmed response rate in 109 heavily pretreated patients.
- Median progression-free survival was 9.5 months; TD Cowen analysts called that clearly better than the 5.6 months cited for AbbVie's Elahere.
- Activity was reported regardless of prior Elahere treatment and in patients with low or no FRα expression.
Cross-trial comparisons flatter whoever runs the later study, so I'd discount the 'clearly superior' framing. Still, activity in low-FRα and post-Elahere patients is the more interesting claim: it widens the addressable population beyond Elahere's high-expressor label. It also supports the case for the ProfoundBio buy.
Industry NewsAbbVieSTAT News
AbbVie's Tavapadon (Juvmo) Pill Wins FDA Approval for Parkinson's Disease
- FDA approved AbbVie's Juvmo (tavapadon), a once-daily oral pill for Parkinson's disease, usable alone early on or alongside levodopa for motor fluctuations.
- It's the first selective D1/D5 dopamine receptor partial agonist approved for Parkinson's, a mechanism distinct from older D2/D3 agonists, aimed at controlling motor symptoms with fewer impulse-control or sleep-attack risks.
- AbbVie gained tavapadon via its 2023 Cerevel Therapeutics acquisition; US launch is planned October 2026.
This is AbbVie's first tangible payoff from the $8.7B Cerevel bet — proof the deal wasn't just pipeline padding. But novelty alone won't move share: Parkinson's prescribing is sticky, generics dominate, and neurologists switch stable patients reluctantly. The cleaner side-effect profile is a real wedge, yet formulary inertia will decide if it's more than a niche add-on.